Cigna Group stock: Piper Sandler cuts target to 360 dollars
Published on 11/13/2026 at 16:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst outlook turns more cautious
- Piper Sandler cited a contracting rebate pool and weaker commercial coverage of GLP-1 medicines.
- Pharmacy benefit services earnings could decline by a high-single-digit percentage in calendar year 2027, with further margin erosion.
- Cigna raised its 2026 adjusted earnings floor to at least 30.60 dollars per share after a third-quarter beat.
Piper Sandler lowered its price target for Cigna Group on Thursday, November 12, while keeping an Overweight rating on the shares. The analyst cited pressure from a contracting rebate pool and weaker commercial coverage of GLP-1 medicines, according to Investing.com.
Why the target moved
Piper Sandler now expects earnings from Cigna's pharmacy benefit services business to decline by a high-single-digit percentage in calendar year 2027, with additional margin erosion. The firm said it was optimistic, but not confident, that the business would reach a trough in 2027.
The revised target applies the same 10-times multiple to lower 2028 adjusted earnings estimates. Piper Sandler's Overweight view depends on Cigna preserving the economics of its business through the Signature transition, while the target still assigns meaningful value to the pharmacy benefit services operation.
Strong quarter, mixed signals
Cigna reported adjusted third-quarter earnings of 7.98 dollars per share and revenue of 73.7 billion dollars, beating Wall Street expectations. Management subsequently lifted the full-year 2026 adjusted earnings outlook to at least 30.60 dollars per share.
The company also set a 2027 adjusted earnings floor of 33.00 dollars per share. That outlook remains exposed to pharmacy pricing, rebate economics, GLP-1 coverage and the planned exit from the ACA exchange business.
What investors watch next
The key test is whether Cigna can convert its stronger 2026 earnings base into durable growth while protecting margins during the Signature transition. Execution in pharmacy benefits and the ACA exit will remain central to the longer-term valuation.
Cigna Group stock last traded at 266.10 euros on Lang & Schwarz at 16:05 CET on Friday, November 13, 2026.
Cigna Group at a glance
- Company: Cigna Group
- ISIN: US1255231003
- Ticker: CI
- Primary exchange: New York Stock Exchange
- Trading venue: Lang & Schwarz
- Last quoted: 266.10 euros at 16:05 CET on November 13, 2026
- Analyst action: Piper Sandler target reduced to 360 dollars from 370 dollars
- Rating: Overweight retained
Broader market coverage is available in Current market reports.
